Blackrock Inc vs Moderna, Inc. — how do they compare? Blackrock Inc trades at $1,154.12 (market cap $177.92B), while Moderna, Inc. trades at $63.7 (market cap $24.18B). The key difference: Blackrock Inc is far larger — about 7.4× Moderna, Inc.'s market cap, and Blackrock Inc pays a 2% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| BLK | MRNA | |
|---|---|---|
Market Cap | $177.92B | $24.18B |
Volume | 641,547 | — |
Sector | Financials | Health |
52-Week High | $1.20K | $81.80 |
52-Week Low | $922.90 | $22.36 |
Enterprise Value | $179.02B | $20.33B |
Dividend Yield | 2% | — |
Signals from Pluang's Aura AI — not financial advice
BLK trades at $1,159.09, up 2.45% today, with strong technical and fundamental momentum. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth accelerated to $24.22 billion in 2025, though net income margin dipped to 22.93%. Recent news highlights BlackRock's involvement in a $500 billion AI financing initiative with Nvidia and other Wall Street firms, signaling strategic positioning in emerging technology investments.
Outlook remains positive with analyst consensus at Buy (78.79%) and a $1,350 price target, though overbought RSI levels and legal scrutiny over mutual fund practices present near-term risks. The company's expansion into tokenized money market products and sustained dividend payments support long-term growth, but investors should monitor margin pressures and regulatory developments.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Trailing returns across standard periods
Latest headlines on both assets
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →